Tobias Gustavsson

An enthusiastic, adaptive and initiative-taking researcher interested in molecular imaging, drug delivery over the blood-brain barrier (BBB), and intra-brain distribution of therapeutic proteins. Four years of experience with in vivo work, immunoPET/SPECT, immunotherapy, antibody production and antibody radiochemistry. Abilities to work both independently and in a team setting. Particularly enjoying collaboration with the team to gain new knowledge and solve challenges. Highly motivated and eager to grow as a researcher with a drive to develop new treatments and diagnostic tools for CNS diseases. Committed [Job Title] with [Number] years of experience using cutting edge technology to generate and share important information with academic community. Networked with elite research teams from [Type] institutions to develop and improve research protocols for field. Conducted complicated research with integrity and great attention to detail.

• Biomarkers in neurodegenerative disorders, Gothenburg, Sweden, 2021
• Molecular Interaction on living cells using LigandTracer, Uppsala, Sweden, 2019
• PET pharmacokinetic course, Imperial College, London, United Kingdom, 2018

• European Association of Nuclear Medicine, 2020, oral presentation, virtual conference
• 14th International Conference of Alzheimer’s and Parkinson’s diseases, 2019, poster presentation, Lisbon, Portugal
• Neuroreceptor mapping conference, 2018, poster presentation, London, United Kingdom
• 5th International Conference on Molecular Neurodegeneration, 2018, poster presentation, Stockholm, Sweden

• Schlein E, Syvänen S, Rokka J, Gustavsson T, Rossin R, Robillard M, Eriksson J, Sehlin D., Functionalization of Radiolabeled Antibodies to Enhance Peripheral Clearance for High Contrast Brain Imaging., Molecular Pharmaceutics, 2022, 19, 11, 4111-4122
• Syvänen S, Meier SR, Roshanbin S, Xiong M, Faresjö R, Gustavsson T, Bonvicini G, Schlein E, Aguilar X, Julku U, Eriksson J, Sehlin D, PET imaging in Preclinical Anti-Aβ Drug Development., Pharmaceutical Research, 2022, May, 2
• Rofo F, Buijs J, Falk R, Honek K, Lannfelt L, Lilja AM, Metzendorf NG, Gustavsson T, Sehlin D, Söderberg L, Hultqvist G., Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta., Translational Neurodegeneration, 2021, 10, 38